ORCHID Chronic Rhinosinusitis with Nasal Polyps Study

Study Title

Efficacy and safety study of benralizumab for patients with eosinophilic chronic rhinosinusitis with nasal polyps

Study duration

Up to 2.5 years

  • Part A: 50% of participants receive the active medication and 50% receive placebo (60 weeks)
  • Part B:  All participants receive the active medication (56 weeks)

Part A: 11 visits

Part B: 8 visits

Main entry criteria
  • 18-75 years of age
  • Have nasal polyps affecting both nostrils
  • Have asthma
  • Experience symptoms due to nasal polyps including nasal blockage, nasal congestion, runny nose, postnasal drip, headache, facial pain, facial pressure, reduced sense of smell and difficulty sleeping.
  • Be willing to use Nasonex to treat nasal polyps, in additional to receiving the study medication, for the duration of the study

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

  • Nasal endoscopies
  • Sinus CT Scan
  • Questionnaires
  • ECGs
  • Blood tests
  • Vital signs

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $70 per visit for your time and travel.